JP2016185981A5 - - Google Patents

Download PDF

Info

Publication number
JP2016185981A5
JP2016185981A5 JP2016137228A JP2016137228A JP2016185981A5 JP 2016185981 A5 JP2016185981 A5 JP 2016185981A5 JP 2016137228 A JP2016137228 A JP 2016137228A JP 2016137228 A JP2016137228 A JP 2016137228A JP 2016185981 A5 JP2016185981 A5 JP 2016185981A5
Authority
JP
Japan
Prior art keywords
seq
chain
amino acid
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016137228A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016185981A (ja
JP6162864B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016185981A publication Critical patent/JP2016185981A/ja
Publication of JP2016185981A5 publication Critical patent/JP2016185981A5/ja
Application granted granted Critical
Publication of JP6162864B2 publication Critical patent/JP6162864B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016137228A 2006-08-14 2016-07-12 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療 Active JP6162864B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2006221230 2006-08-14
JP2006221230 2006-08-14
JP2007019108 2007-01-30
JP2007019108 2007-01-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014175480A Division JP5972325B2 (ja) 2006-08-14 2014-08-29 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療

Publications (3)

Publication Number Publication Date
JP2016185981A JP2016185981A (ja) 2016-10-27
JP2016185981A5 true JP2016185981A5 (enExample) 2017-04-13
JP6162864B2 JP6162864B2 (ja) 2017-07-12

Family

ID=39082111

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2008529863A Active JP5317697B2 (ja) 2006-08-14 2007-08-14 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療
JP2013043041A Active JP5651726B2 (ja) 2006-08-14 2013-03-05 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療
JP2014175480A Active JP5972325B2 (ja) 2006-08-14 2014-08-29 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療
JP2016137228A Active JP6162864B2 (ja) 2006-08-14 2016-07-12 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2008529863A Active JP5317697B2 (ja) 2006-08-14 2007-08-14 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療
JP2013043041A Active JP5651726B2 (ja) 2006-08-14 2013-03-05 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療
JP2014175480A Active JP5972325B2 (ja) 2006-08-14 2014-08-29 抗Ｄｅｓｍｏｇｌｅｉｎ３抗体を用いる癌の診断および治療

Country Status (7)

Country Link
US (2) US20100092457A1 (enExample)
EP (3) EP2548576B1 (enExample)
JP (4) JP5317697B2 (enExample)
AU (1) AU2007285217B2 (enExample)
BR (1) BRPI0713086A2 (enExample)
CA (1) CA2658050A1 (enExample)
WO (1) WO2008020586A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003271175A1 (en) * 2002-10-11 2004-05-04 Masahiro Abe Cell death-inducing agent
TW200530269A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
KR20060130606A (ko) * 2003-12-12 2006-12-19 추가이 세이야쿠 가부시키가이샤 세포사 유도제
JPWO2005056602A1 (ja) * 2003-12-12 2008-03-06 中外製薬株式会社 アゴニスト活性を有する改変抗体のスクリーニング方法
WO2005056605A1 (ja) * 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha ３量体以上の受容体を認識する改変抗体
EP1757686A4 (en) * 2004-04-09 2008-03-12 Chugai Pharmaceutical Co Ltd Cell death inducer
EP1870458B1 (en) * 2005-03-31 2018-05-09 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2 STRUCTURAL ISOMERS
WO2006123724A1 (ja) * 2005-05-18 2006-11-23 The University Of Tokushima 抗hla抗体を利用した新規医薬品
CN101262885B (zh) 2005-06-10 2015-04-01 中外制药株式会社 含有sc(Fv)2的药物组合物
CA2610987C (en) * 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
MX2009000487A (es) * 2006-07-13 2009-01-27 Chugai Pharmaceutical Co Ltd Inductor de muerte celular.
EP2548576B1 (en) 2006-08-14 2016-11-30 Chugai Seiyaku Kabushiki Kaisha Diagnosis of cancer using anti-desmoglein-3 antibodies
WO2008085987A2 (en) * 2007-01-09 2008-07-17 The Trustees Of The University Of Pennsylvania Drug delivery to human tissues by single chain variable region antibody fragments cloned by phage display
CL2008000719A1 (es) * 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
US8187601B2 (en) 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
BRPI0919377A2 (pt) 2008-09-26 2016-09-27 Dana Farber Cancer Inst Inc anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
EP2308897A1 (en) * 2009-10-09 2011-04-13 Pierre Fabre Medicament Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer
KR20130065665A (ko) 2010-05-11 2013-06-19 아베오 파마슈티컬즈, 인크. 항-fgfr2 항체
AU2011309114B2 (en) 2010-09-28 2015-03-19 Nb Health Laboratory Co., Ltd. Antihuman CCR7 antibodies, hybridoma, nucleic acid, vector, cell, medicinal composition, and antibody-immobilized carrier
WO2012154983A2 (en) 2011-05-10 2012-11-15 Biocare Medical, Llc Systems and methods for anti-pax8 antibodies
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
DK2900265T3 (en) 2012-09-27 2018-08-20 Biocare Medical Llc Anti-Uroplakin II Antibodies, Systems and Methods
US10502743B2 (en) 2012-10-09 2019-12-10 Konica Minolta, Inc. Method for detecting lung squamous cell carcinoma
WO2014100220A2 (en) * 2012-12-18 2014-06-26 Biocare Medical, Llc Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
DK2962113T3 (da) 2013-02-28 2019-07-01 Biocare Medical Llc Systemer og fremgangsmåder med anti-p40-antistoffer
ES2765423T3 (es) 2013-10-03 2020-06-09 Biocare Medical Llc Sistemas y procedimientos de anticuerpos anti-SOX10
WO2017147247A1 (en) * 2016-02-23 2017-08-31 Pires Eusebio S Anti-sas1b antibodies and methods of use
US11993645B2 (en) 2017-01-11 2024-05-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions comprising R-Spondin (RSPO) surrogate molecules
JP7305543B2 (ja) 2017-01-26 2023-07-10 スロゼン オペレーティング， インコーポレイテッド 組織特異的Ｗｎｔシグナル増強分子およびその使用
EP3773658A4 (en) 2018-04-06 2022-04-27 Dana-Farber Cancer Institute, Inc. KIR3DL3 AS HLA2 RECEPTOR, ANTI-HHLA2 ANTIBODY AND ITS USES
WO2020014271A1 (en) 2018-07-09 2020-01-16 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses
US20240075161A1 (en) * 2019-10-28 2024-03-07 Augusta University Research Institute, Inc. Engineered exosomes to detect and deplete pro-tumorigenic macrophages
JP2023549854A (ja) 2020-11-16 2023-11-29 スロゼン オペレーティング， インコーポレイテッド 肝臓特異的Ｗｎｔシグナル増強分子およびその使用
CN113476601B (zh) * 2021-08-24 2022-05-20 知佰幸细胞库(浙江)有限公司 干细胞细胞因子联合海藻多糖制备的药物或化妆品
KR20240125951A (ko) * 2021-12-14 2024-08-20 다나-파버 캔서 인스티튜트 인크. 질환을 치료하기 위한 조성물 및 방법

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JPS6459878A (en) 1987-08-31 1989-03-07 Matsushita Electric Industrial Co Ltd Semiconductor laser protective circuit
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
EP0656941B1 (en) 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
KR100261941B1 (ko) 1994-07-13 2000-07-15 나가야마 오사무 사람의 인터루킨-8에 대한 재구성 사람항체
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
AU759144B2 (en) 1998-05-05 2003-04-03 Adherex Technologies Inc. Compounds and methods for modulating nonclassical cadherin-mediated functions
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CN102311986B (zh) 2000-10-06 2015-08-19 协和发酵麒麟株式会社 产生抗体组合物的细胞
JP2005500018A (ja) 2001-04-02 2005-01-06 アイデック ファーマスーティカルズ コーポレイション ＧｎＴＩＩＩと同時発現する組換え抗体
JP2005527180A (ja) 2001-04-18 2005-09-15 プロテイン デザイン ラブス， インコーポレイテッド 肺がんの診断方法、肺がんの修飾因子の組成及びスクリーニングの方法
US7550562B2 (en) * 2001-09-04 2009-06-23 Keio University Pemphigus monoclonal antibody
WO2003104453A1 (ja) 2002-06-05 2003-12-18 中外製薬株式会社 抗体作製方法
DE102004023187A1 (de) * 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
US20060057559A1 (en) * 2004-06-23 2006-03-16 Rigel Pharmaceuticals, Inc. High-throughput cell migration screening assay
EP2208783A1 (en) 2004-12-22 2010-07-21 Chugai Seiyaku Kabushiki Kaisha Method of producing an antibody using a cell in which the function of fucose transporter is inhibited
EP2548576B1 (en) 2006-08-14 2016-11-30 Chugai Seiyaku Kabushiki Kaisha Diagnosis of cancer using anti-desmoglein-3 antibodies

Similar Documents

Publication Publication Date Title
JP2016185981A5 (enExample)
JP2020501532A5 (enExample)
JP2017176174A5 (enExample)
JP2017114866A5 (enExample)
JP2020022464A5 (enExample)
JP2018504907A5 (enExample)
JP2016196468A5 (enExample)
JP2014205674A5 (enExample)
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
MX392340B (es) Anticuerpo anti cd73 humana.
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
JP2013539361A5 (enExample)
JP2012116856A5 (enExample)
JP2012126742A5 (enExample)
JP2014012688A5 (enExample)
JP2012143232A5 (enExample)
CL2012002095A1 (es) Polipéptido de unión biparatópico que comprende un primer dominio variable individual de inmunoglobulina (ig) que se une específicamente a un primer epítopo del péptido ß-amiloide (ßa) y un segundo dominio variable de ig que se une específicamente a un segundo epítopo del ßa, donde dichos epítopos del ßa no son idénticos; ácido nucleico que lo codifica; vector; célula hospedera; composición farmacéutica; método de preparación; y su uso en el tratamiento y/o prevención de depósitos del ßa
JP2012502649A5 (enExample)
JP2013538057A5 (enExample)
JP2011526480A5 (enExample)
JP2017534262A5 (enExample)
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
JP2012034692A5 (enExample)
JP2014518883A5 (enExample)
JP2016116527A5 (enExample)